Repligen Agrees to Buy Novozymes Biopharma Sweden to Increase its Revenue Potential
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 16 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1614 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Repligen has agreed to acquire the business of Novozymes Biopharma Sweden in a cash transaction worth up to €21 M (US$29...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS